Biliary Tract Cancer Clinical Trials in Seoul
8 recruitingSeoul, South Korea
Showing 1–8 of 8 trials
Recruiting
Phase 2
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
Biliary Tract CancerHepatocellular Carcinoma
AstraZeneca294 enrolled60 locationsNCT05775159
Recruiting
Phase 3
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
Biliary Tract Cancer
AstraZeneca620 enrolled266 locationsNCT06467357
Recruiting
Phase 3
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
Biliary Tract Cancer
Jazz Pharmaceuticals286 enrolled184 locationsNCT06282575
Recruiting
Phase 3
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
Biliary Tract Cancer
AstraZeneca1,100 enrolled168 locationsNCT07221253
Recruiting
Phase 1Phase 2
Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors
Biliary Tract CancerHead and Neck Squamous Cell CarcinomaSolid Tumor
TiumBio Co., Ltd.140 enrolled11 locationsNCT05784688
Recruiting
Phase 1Phase 2
First-line Trastuzumab, Gemcitabine, Cisplatin and Nivolumab in Advanced HER2- Positive Biliary Tract Cancer: a Multicenter, Open-label, Single-arm Phase Ib/II Trial (HERBOT)
HER2 Positive Advanced/Metastatic/Nonresectable Biliary Tract Cancer
Yonsei University44 enrolled1 locationNCT05749900
Recruiting
Phase 2
Olaparib With or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy
Biliary Tract CancerDNA Damage Repair Deficiency
Asan Medical Center62 enrolled1 locationNCT05222971
Recruiting
Phase 2Phase 3
Study of SMT-NK Inj. Plus Pembrolizumab vs Pembrolizumab Monotherapy in Patients With Advanced Biliary Tract Cancer
Biliary Tract Cancer
SMT bio Co., Ltd.128 enrolled3 locationsNCT05429697